Introduction
hypoglycaemia, diabetes
HYPOGLYCAEMIA, TYPE 2 DIABETES, DIABETES
Despite ongoing advances in diabetes therapy, hypoglycaemia and the fear of hypoglycaemia are still considerable barriers for optimal glycaemic control in diabetes [In type 2 diabetes, longer duration of diabetes and increased time since initiation of insulin therapy are both associated with diminishing hypoglycaemia awareness and blunted counterregulation [Insulin icodec is a basal insulin that is being developed for once-weekly administration [As icodec is a novel basal insulin, the glucodynamics, counterregulation and safety associated with hypoglycaemia require further characterisation. This trial investigated hypoglycaemia frequency, time to hypoglycaemia, recovery from hypoglycaemia and overall safety after double or triple doses of once-weekly icodec vs once-daily glargine U100 in type 2 diabetes. Furthermore, symptomatic and hormonal counterregulatory responses to hypoglycaemia were compared between icodec and glargine U100 in a subgroup analysis that only included individuals when they actually experienced hypoglycaemia after a double or triple dose of either insulin product. To our knowledge, this is the first study to investigate the symptomatic and endocrine responses to hypoglycaemia induced by a basal insulin analogue in individuals with type 2 diabetes.